These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
264 related articles for article (PubMed ID: 12867066)
21. Antisense oligonucleotides: target validation and development of systemically delivered therapeutic nanoparticles. Zhang C; Pei J; Kumar D; Sakabe I; Boudreau HE; Gokhale PC; Kasid UN Methods Mol Biol; 2007; 361():163-85. PubMed ID: 17172711 [TBL] [Abstract][Full Text] [Related]
22. Potential roles of antisense oligonucleotides in cancer therapy. The example of Bcl-2 antisense oligonucleotides. Dias N; Stein CA Eur J Pharm Biopharm; 2002 Nov; 54(3):263-9. PubMed ID: 12445555 [TBL] [Abstract][Full Text] [Related]
24. Oblimersen sodium (G3139 Bcl-2 antisense oligonucleotide) therapy in Waldenstrom's macroglobulinemia: a targeted approach to enhance apoptosis. Frankel SR Semin Oncol; 2003 Apr; 30(2):300-4. PubMed ID: 12720157 [TBL] [Abstract][Full Text] [Related]
25. Antisense cancer therapy: the state of the science. Kushner DM; Silverman RH Curr Oncol Rep; 2000 Jan; 2(1):23-30. PubMed ID: 11122821 [TBL] [Abstract][Full Text] [Related]
26. Rational design of sequence-specific oncogene inhibitors based on antisense and antigene oligonucleotides. Hélène C Eur J Cancer; 1991; 27(11):1466-71. PubMed ID: 1835863 [TBL] [Abstract][Full Text] [Related]
27. Cytotoxicity of etoposide in cancer cell lines in vitro after BCL-2 and C-RAF gene silencing with antisense oligonucleotides. Sypniewski D; Bednarek I; Gałka S; Loch T; Błaszczyk D; Sołtysik D Acta Pol Pharm; 2013; 70(1):87-97. PubMed ID: 23610963 [TBL] [Abstract][Full Text] [Related]
29. Bcl-2 antisense in the treatment of human malignancies: a delusion in targeted therapy. Gjertsen BT; Bredholt T; Anensen N; Vintermyr OK Curr Pharm Biotechnol; 2007 Dec; 8(6):373-81. PubMed ID: 18289046 [TBL] [Abstract][Full Text] [Related]
30. Use of antisense oligonucleotides: advantages, controls, and cardiovascular tissue. Golden T; Dean NM; Honkanen RE Microcirculation; 2002 Jan; 9(1):51-64. PubMed ID: 11896559 [TBL] [Abstract][Full Text] [Related]
31. Induction of apoptosis in small-cell lung cancer cells by an antisense oligodeoxynucleotide targeting the Bcl-2 coding sequence. Ziegler A; Luedke GH; Fabbro D; Altmann KH; Stahel RA; Zangemeister-Wittke U J Natl Cancer Inst; 1997 Jul; 89(14):1027-36. PubMed ID: 9230884 [TBL] [Abstract][Full Text] [Related]
32. Modulation of lipoprotein metabolism by antisense technology: preclinical drug discovery methodology. Crooke RM; Graham MJ Methods Mol Biol; 2013; 1027():309-24. PubMed ID: 23912993 [TBL] [Abstract][Full Text] [Related]
33. Oblimersen Bcl-2 antisense: facilitating apoptosis in anticancer treatment. Klasa RJ; Gillum AM; Klem RE; Frankel SR Antisense Nucleic Acid Drug Dev; 2002 Jun; 12(3):193-213. PubMed ID: 12162702 [TBL] [Abstract][Full Text] [Related]
34. Using RNA-seq to Assess Off-Target Effects of Antisense Oligonucleotides in Human Cell Lines. Michel S; Schirduan K; Shen Y; Klar R; Tost J; Jaschinski F Mol Diagn Ther; 2021 Jan; 25(1):77-85. PubMed ID: 33314011 [TBL] [Abstract][Full Text] [Related]
35. Antisense strategy: biological utility and prospects in the treatment of hematological malignancies. Warzocha K; Wotowiec D Leuk Lymphoma; 1997 Jan; 24(3-4):267-81. PubMed ID: 9156656 [TBL] [Abstract][Full Text] [Related]